(NASDAQ: LXEO) Lexeo Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 9.74%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.81%.
Lexeo Therapeutics's earnings in 2025 is -$109,307,000.On average, 5 Wall Street analysts forecast LXEO's earnings for 2025 to be -$85,183,494, with the lowest LXEO earnings forecast at -$105,234,480, and the highest LXEO earnings forecast at -$54,111,105. On average, 4 Wall Street analysts forecast LXEO's earnings for 2026 to be -$65,730,054, with the lowest LXEO earnings forecast at -$87,308,102, and the highest LXEO earnings forecast at -$37,844,577.
In 2027, LXEO is forecast to generate -$42,160,186 in earnings, with the lowest earnings forecast at -$53,447,165 and the highest earnings forecast at -$30,873,207.